Followers | 55 |
Posts | 2608 |
Boards Moderated | 0 |
Alias Born | 02/04/2014 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 23, 2015 4:45:11 PM
Jun 23, 2015
PharmaCyte Biotech, UTS to Partner on Diabetes Treatment
PharmaCyte Biotech will partner with the University of Technology Sydney (UTS) to co-develop the company’s preclinical treatment for insulin-dependent diabetes that uses its Cell-in-a-Box® technology. The value of the collaboration was not disclosed.
The diabetes treatment consists of Melligen cells—human non-pancreatic insulin-producing cells—developed by UTS researchers, and encapsulated via Cell-in-a-Box, the company’s cellulose-based live cell encapsulation technology.
PharmaCyte Biotech and UTS have signed a research services agreement and a consulting contract. The agreement is designed to fund pivotal studies by Professor Ann Simpson, Ph.D. and colleagues to conduct, with the goal of helping fully characterize the parameters by which Melligen cells produce insulin on-demand when encapsulated using Cell-in-a-Box.
The consulting contract is intended to allow Dr. Simpson to devote sufficient time to working with PharmaCyte Biotech and its international Diabetes Consortium as it pursues development of the company’s diabetes treatment.
“We are particularly pleased that Professor Simpson has agreed to join us as a consultant because, not only was she a founding member of our Diabetes Consortium, her expertise in dealing with the Melligen cells will undoubtedly continue to be indispensable as we move forward in our efforts to find an effective treatment for all those who are in need of insulin to live a normal life,” PharmaCyte Biotech CEO Kenneth L. Waggoner said in a statement.
According to the company, the consortium consists of prominent investigators from institutions in several countries. The consortium was formed to facilitate studies that will be needed before clinical trials can be undertaken on the diabetes treatment.
The company plans to use Cell-in-a-Box as a platform for treatments for diabetes as well as several types of cancer, including advanced, inoperable pancreatic cancer.
PharmaCyte Biotech’s lead product is a pancreatic cancer treatment that involves low doses of the chemotherapy prodrug ifosfamide, together with encapsulated live cells that convert ifosfamide into its active form, in capsules placed as close to the tumor as possible.
The company said it is also developing cancer treatments based on cannabinoids.
http://www.genengnews.com/gen-news-highlights/pharmacyte-biotech-uts-to-partner-on-diabetes-treatment/81251423/
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM